Wade T. Iams, MD

Wade Iams, MD, is the director of Lung Cancer Research at Tennessee Oncology in Nashville.

Articles

Unmet Needs Research Aims to Address in Early-Stage NSCLC

August 14th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss ongoing research in early-stage non–small cell lung cancer.

Closing Perspectives: Unmet Needs, Emerging Advances, and the Future of Early-Stage NSCLC Treatment

August 12th 2025

Panelists discuss how future advances will focus on biomarker-driven personalized approaches, platform trials to increase pathologic complete response rates, circulating tumor DNA (ctDNA)-guided therapy escalation and de-escalation, and the critical importance of comprehensive molecular testing in the neoadjuvant setting.

How Immunotherapy Could Continue to Affect Early-Stage NSCLC Management

August 7th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy could continue to reshape early NSCLC management.

Factors Influencing Adjuvant Treatment Decisions in Early-Stage NSCLC

August 7th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss factors that affect adjuvant treatment decisions in early non–small cell lung cancer.

PACIFIC-R 5-Year Follow-Up: Real-World Outcomes and Implications for Unresectable NSCLC Treatment

August 5th 2025

Panelists discuss how the PACIFIC-R real-world data demonstrates excellent long-term outcomes with a median survival of 60 months, validating the durvalumab consolidation approach while addressing management strategies for patients who progress on or after immunotherapy.

Surgical Attrition in Resectable NSCLC: Risk Factors, Patient Communication, and Strategies to Optimize Continuity of Care

August 5th 2025

Panelists discuss how neoadjuvant chemoimmunotherapy maintains acceptable surgical safety profiles with mortality rates under 4% and how technical complexity primarily stems from hilar lymph node involvement rather than the systemic therapy itself, requiring experienced surgeons to handle these cases.

Clinical Utility of ctDNA in Guiding Perioperative Treatment Decisions in Early-Stage NSCLC

July 29th 2025

Panelists discuss how circulating tumor DNA (ctDNA) serves as a promising biomarker for identifying patients at higher risk who may benefit from therapy escalation, though they acknowledge the current lack of prospective data on how to act therapeutically on positive ctDNA results.

Optimizing Adjuvant Therapy Decisions in Resectable NSCLC: Integrating Pathologic Response, PD-L1, and Nodal Status

July 29th 2025

Panelists discuss how treatment decisions should integrate multiple factors, including pathologic complete response (pCR), PD-L1 status, and nodal involvement, with particular emphasis on continuing adjuvant therapy for N2 disease and non-PCR patients despite the complexity of using residual viable tumor as a decision-making tool.

Updated Findings From CheckMate-816 for Neoadjuvant Nivolumab Plus Chemo in Resectable NSCLC

July 24th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated findings for neoadjuvant nivolumab plus chemotherapy in resectable NSCLC.

Surgical Outcomes From CheckMate-77T With Perioperative Nivolumab in Resectable NSCLC

July 24th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss surgical outcomes from CheckMate-77T for perioperative nivolumab in resectable NSCLC.

FDA Green-Lights Subcutaneous Nivolumab: What It Means for Early-Stage NSCLC Care

July 22nd 2025

Panelists discuss how subcutaneous (SQ) nivolumab administration offers patient convenience and potential logistical advantages, particularly in the maintenance setting, though they acknowledge limited current adoption and need for more biological data on efficacy differences.

MDT Management of Borderline Resectable Early-Stage NSCLC and Delayed Surgery After Neoadjuvant IO

July 22nd 2025

Panelists discuss how borderline resectable patients can be made resectable through neoadjuvant chemoimmunotherapy when surgeons have clear, objective goals for what they aim to achieve rather than vague hopes to make surgery “less scary.”

Perioperative Nivolumab in Resectable NSCLC: Updated Data From CheckMate-77T

July 17th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated data from CheckMate-77T of perioperative nivolumab in resectable NSCLC.

How Immunotherapy Is Affecting Perioperative Treatment Decisions in Early-Stage NSCLC

July 17th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy is affecting perioperative treatment in early-stage non–small cell lung cancer.

Expert Perspectives in Challenging Situations: Progression After Neoadjuvant Chemoimmunotherapy

July 15th 2025

Panelists discuss how to manage patients who cannot proceed to surgery after neoadjuvant chemoimmunotherapy by pivoting to definitive concurrent chemoradiation with reduced-dose chemotherapy, while emphasizing the need to distinguish true progression from inflammatory changes.

ASCO 2025 Real-World Data on Neoadjuvant Therapy in Stage II to III NSCLC: Surgical Outcomes and Clinical Implications

July 15th 2025

Panelists discuss how real-world data from the Flatiron Health database revealed that surgical completion rates after neoadjuvant therapy are lower in community practice (65%) compared with clinical trials, particularly for patients with poor performance status or more advanced stage disease.

Surgical Perspectives: Who Are the Best Candidates for Neoadjuvant Chemoimmunotherapy?

July 8th 2025

Panelists discuss how surgeons evaluate candidates for neoadjuvant chemoimmunotherapy by emphasizing that all patients with stage II and III disease should be considered regardless of PD-L1 or mutation status, while highlighting the importance of multidisciplinary collaboration in treatment decisions.

CheckMate 77T: Updated Survival and Biomarker Insights Shaping Early-Stage NSCLC Care

July 8th 2025

Panelists discuss how the CheckMate 77T perioperative trial updates showed that even patients receiving fewer than 4 cycles of neoadjuvant therapy still benefited, and circulating tumor DNA (ctDNA) clearance serves as an independent biomarker for predicting outcomes regardless of pathologic response status.

CheckMate 816 at ASCO 2025: OS Update and Impact on Early-Stage NSCLC Care

June 27th 2025

Panelists discuss how the CheckMate 816 overall survival data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated a significant survival benefit with neoadjuvant chemoimmunotherapy, particularly in patients with higher PD-L1 expression and those achieving pathologic complete responses (pCRs).

Resectable Early-Stage NSCLC: How the Standard of Care Is Evolving

June 27th 2025

Panelists discuss how the standard of care for resectable early-stage non–small cell lung cancer (NSCLC) has evolved from adjuvant chemotherapy alone to neoadjuvant chemoimmunotherapy and perioperative approaches that combine preoperative treatment with continued immunotherapy after surgery.